Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Academic conference

    • Home
    • Academic conference
    • Page 8
Company Drug

CANbridge Pharmaceuticals Presents Positive Phase I Data for CAN106 at EHA Congress

Fineline Cube Jun 13, 2022

China-based rare disease firm CANbridge Pharmaceuticals Inc. (HKG: 1228) released the latest data from a...

Company Drug

Ascentage Pharma’s Lisaftoclax Shows Promising Results in Phase I Trial for Non-Hodgkin Lymphoma

Fineline Cube Jun 13, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) announced the publication of Phase I clinical study results for...

Posts pagination

1 … 7 8

Recent updates

  • Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda
  • Ab&B Bio-Tech Secures NMPA Clinical Approval for mRNA RSV Vaccine, Addressing Critical Unmet Need in China
  • Mabwell Bioscience Secures FDA Clearance for 9MW5211 in IBD, Advances Multi-Indication Autoimmune Pipeline
  • Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership
  • Allergan Aesthetics Secures First-in-China NMPA Approval for Juvéderm VOLUMA Temple Indication
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda

Company Drug

Ab&B Bio-Tech Secures NMPA Clinical Approval for mRNA RSV Vaccine, Addressing Critical Unmet Need in China

Company Drug

Mabwell Bioscience Secures FDA Clearance for 9MW5211 in IBD, Advances Multi-Indication Autoimmune Pipeline

Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.